2 research outputs found
Using the latest resistance score to predict etravirine (ETV) resistance in naïve and NNRTI-failing patients
Methods A set of 17 mutations (V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S, M230L) were found associated with ETV resistance in the Phase III DUET-1 and DUET-2 trials. Recently, a different score was assigned to each mutation (i.e. Y181C/I have the highest score: 3). An overall score of ≤4 was associated with reduced response and a score between 2.5–3.5 with intermediate response (reference). ETV resistance was calculated from a large database of patients undergoing genotypic resistance test
Antiretroviral treatment efficacy after mutations reversion during T20 monotherapy, an alternative strategy in multi-failed HIV-1 infected patients
Purpose of the study Monotherapy maintenance with 3TC after multiple therapeutic failure, helps in maintaining the number of CD4, but, at the same time, slows down the speed of reversion of mutations usually achieved during complete interruption of therapy. Monotherapy with enfuvirtide (T20) can be an interesting alternative to 3TC monotherapy, due to the CD4-enhancement typical of this drug even during therapeutic failure. Aim of this study was to assess, in a proof-of-concept study, the efficacy of T20-monotherapy to maintain the levels of CD4, to allow reversal of mutations in the pol gene, and eventually to favor long-term success of subsequent HAART